Within the last quarter, Amgen AMGN has observed the following analyst ratings:
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 6 | 8 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 0 | 0 | 0 |
| 2M Ago | 1 | 2 | 6 | 0 | 0 |
| 3M Ago | 2 | 2 | 2 | 0 | 0 |
Within the last quarter, 18 analysts provided 12-month price targets for Amgen. The average target is $293.06, with a high estimate of $326.00 and a low estimate of $240.00.
Get a quick summary of 18 analysts' ratings for Amgen over the last 3 months. More bullish views suggest a positive outlook, while more bearish views imply a negative sentiment.
A notable 5.07% increase in the average price target has occurred over the past month.
Diving into Analyst Ratings: An In-Depth Exploration
Explore the analyses of financial experts and analysts, gaining insights into their recent assessments for Amgen. The Ratings Table below delivers a detailed overview of the actions undertaken by key analysts, their current ratings, and price targets. Uncover valuable perspectives on possible market trends and investor sentiment by understanding the perceptions of these experts towards the company.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Evan David Seigerman | BMO Capital | Raises | Outperform | $326.00 | $286.00 |
| Gregory Renza | RBC Capital | Raises | Outperform | $300.00 | $256.00 |
| Robyn Karnauskas | Truist Securities | Maintains | Buy | $320.00 | - |
| James Shin | Deutsche Bank | Announces | Hold | $240.00 | - |
| Gregory Renza | RBC Capital | Raises | Sector Perform | $256.00 | $253.00 |
| Robyn Karnauskas | Truist Securities | Announces | Buy | $320.00 | - |
| Colin Bristow | UBS | Lowers | Neutral | $268.00 | $272.00 |
| Gregory Renza | RBC Capital | Raises | Sector Perform | $256.00 | $253.00 |
| Terence Flynn | Morgan Stanley | Lowers | Equal-Weight | $291.00 | $300.00 |
| Jay Olson | Oppenheimer | Raises | Outperform | $310.00 | $300.00 |
| Jay Olson | Oppenheimer | Raises | Outperform | $300.00 | $290.00 |
| Chris Schott | JP Morgan | Announces | Neutral | $270.00 | - |
| David Toung | Argus Research | Raises | Buy | $310.00 | $280.00 |
| Terence Flynn | Morgan Stanley | Announces | Equal-Weight | $300.00 | - |
| Michael Yee | Jefferies | Maintains | Buy | $310.00 | $310.00 |
| David Risinger | Leerink Partners | Raises | Outperform | $318.00 | $267.00 |
| Geoff Meacham | B of A Securities | Announces | Neutral | $290.00 | - |
| Jay Olson | Oppenheimer | Raises | Outperform | $290.00 | $280.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Amgen. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Amgen compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Amgen's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Amgen analyst ratings.
Get to Know Amgen Better
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Financial Milestones: Amgen's Journey
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Amgen displayed positive results in 3 months. As of 30 September, 2023, the company achieved a solid revenue growth rate of approximately 3.77%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Amgen's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 25.06% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Amgen's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 23.97%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Amgen's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.91% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a high debt-to-equity ratio of 7.9, Amgen faces challenges in effectively managing its debt levels, indicating potential financial strain.
The Significance of Analyst Ratings Explained
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
